| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Dechant Robert Thomas | Chief Executive Officer, Director | C/O IBEX LIMITED, 1717 PENNSYLVANIA AVENUE NW, SUITE 825, WASHINGTON | Lisa Lenstrohm, Attorney-in-Fact | 12 Feb 2026 | 0001298255 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | IBEX | Common Shares | Award | $0 | +124,582 | +62% | $0.000000 | 324,394 | 06 Feb 2026 | Direct | F1 |
| transaction | IBEX | Common Shares | Tax liability | $664,200 | -18,988 | -5.9% | $34.98 | 305,406 | 06 Feb 2026 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | Reporting Person received this restricted stock award in connection with the vesting of an April 20, 2022 performance share award upon the attainment of certain Issuer Revenue and EBITDA targets for the trailing four (4) quarters. One-third of these shares vested on February 6, 2026. The remaining shares will vest one-third on February 6, 2027 and one-third on February 6, 2028. Vesting of performance share awards and shares issued in respect thereof is subject to the Reporting Person's continued service to the Company with Issuer through the applicable vesting date. |
| F2 | Represents shares withheld for tax purposes upon vesting of restricted stock grant. |